サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1597285

子癇前症診断の世界市場の評価：検査タイプ別、製品タイプ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Preeclampsia Diagnostics Market Assessment, By Test Type, By Product, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 236 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
子癇前症診断の世界市場の評価：検査タイプ別、製品タイプ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年11月26日
発行: Market Xcel - Markets and Data
ページ情報: 英文 236 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の子癇前症診断の市場規模は、2023年の10億7,700万米ドルから2031年に13億8,887万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで3.23%の成長が見込まれます。子癇前症の有病率の増加、女性の健康安全に対する意識の高まり、市場の成長に寄与するさまざまな技術の進歩により、子癇前症診断製品に対する市場需要は予測期間に増加する見込みです。

妊娠中毒症としても知られる子癇前症は、妊娠に特異的な多臓器疾患であり、高血圧の新規発症、しばしば尿中の多量のタンパク、または重大な末端臓器障害に伴う高血圧の新規発症を特徴とし、この疾患はタンパク尿の有無にかかわらず発症する可能性があります。この疾患が現れるのは妊娠20週からです。さらに重症になると、赤血球の破壊や血小板の低下、肝臓の機能障害、腎不全、浮腫、肺水腫による息切れ、視覚障害などが見られるようになります。子癇前症は妊娠高血圧症候群として診断され、その世界の有病率は妊娠の約1～5%であり、この疾患は妊産婦死亡の主因の1つであると認識されています。

妊娠高血圧症候群（子癇前症を含む）は、世界中で出産に関連した症例の中で2番目に頻度の高い死因であり、毎年6万2,000人～7万7,000人が死亡していると推定されています。妊婦におけるこの疾患とその診断方法に対する意識の高まりが、予測期間における子癇前症診断市場の成長要因となる見込みです。例えば、2023年5月19日、Thermo Fisher Scientific Inc.は、妊婦の子癇前症を予測する初の血液検査について米国食品医薬品局（USFDA）から承認を得たと発表しました。この血液検査は妊娠23週～35週の女性を対象としています。

当レポートでは、世界の子癇前症診断市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の子癇前症診断市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 検査タイプ別
    • 製品別
    • エンドユーザー別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 検査タイプ別
    • 製品別
    • エンドユーザー別
    • 地域別

第5章 北米の子癇前症診断市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 検査タイプ別
    • 製品別
    • エンドユーザー別
    • シェア：国別
  • 各国の市場の評価
    • 米国の子癇前症診断市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の子癇前症診断市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の子癇前症診断市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の子癇前症診断市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの子癇前症診断市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場促進要因
  • 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Thermo Fisher Scientific, Inc.
    • Diabetomics, Inc.
    • BioCheck.
    • Sera Prognostics.
    • Bayer, AG.
    • Siemens Healthineers AG.
    • QuidelOrtho Corporation.
    • Beckman Coulter, Inc.
    • PerkinElmer, Inc.
    • Biora Therapeutics, Inc.

第21章 戦略的推奨

第22章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 2. Global Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 3. Global Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Preeclampsia Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 7. North America Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 8. North America Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 9. North America Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Preeclampsia Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 12. United States Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 13. United States Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 14. United States Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 16. Canada Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 17. Canada Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 18. Canada Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 20. Mexico Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 21. Mexico Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 22. Mexico Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 24. Europe Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 25. Europe Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 26. Europe Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Preeclampsia Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 29. Germany Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 30. Germany Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 31. Germany Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 33. France Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 34. France Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 35. France Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 37. Italy Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 38. Italy Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 39. Italy Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 41. United Kingdom Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 42. United Kingdom Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 43. United Kingdom Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 45. Russia Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 46. Russia Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 47. Russia Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 49. Netherlands Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 50. Netherlands Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 51. Netherlands Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 53. Spain Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 54. Spain Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 55. Spain Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 57. Turkey Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 58. Turkey Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 59. Turkey Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 61. Poland Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 62. Poland Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 63. Poland Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 65. South America Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 66. South America Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 67. South America Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Preeclampsia Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 70. Brazil Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 71. Brazil Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 72. Brazil Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 74. Argentina Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 75. Argentina Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 76. Argentina Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 78. Asia-Pacific Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 79. Asia-Pacific Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 80. Asia-Pacific Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Preeclampsia Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 82. India Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 83. India Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 84. India Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 85. India Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 87. China Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 88. China Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 89. China Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 91. Japan Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 92. Japan Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 93. Japan Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 95. Australia Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 96. Australia Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 97. Australia Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 99. Vietnam Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 100. Vietnam Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 101. Vietnam Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 103. South Korea Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 104. South Korea Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 105. South Korea Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 107. Indonesia Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 108. Indonesia Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 109. Indonesia Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 111. Philippines Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 112. Philippines Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 113. Philippines Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 115. Middle East & Africa Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 116. Middle East & Africa Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 117. Middle East & Africa Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Preeclampsia Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 120. Saudi Arabia Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 121. Saudi Arabia Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 122. Saudi Arabia Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 124. UAE Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 125. UAE Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 126. UAE Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Preeclampsia Diagnostics Market, By Value, In USD Million, 2017-2031F
  • Figure 128. South Africa Preeclampsia Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 129. South Africa Preeclampsia Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 130. South Africa Preeclampsia Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Test Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 132. By Product Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
目次
Product Code: MX12282

Global preeclampsia diagnostics market is projected to witness a CAGR of 3.23% during the forecast period 2024-2031, growing from USD 1077.00 million in 2023 to USD 1388.87 million in 2031. The market demand for preeclampsia diagnostic products is anticipated to rise in the forecast period due to the increased prevalence of preeclampsia, rising awareness of women's health safety, and various technological advancements that contribute to the growth of the market.

Preeclampsia, also known as Toxemia, is a multi-system disorder that is specific to pregnancy and is characterized by the new onset of high blood pressure, often with significant amounts of protein in the urine, or by the new onset of high blood pressure along with a significant end-organ damage, the disorder might occur with or without the proteinuria. When the condition appears, it starts at 20 weeks of gestation. In more severe stages of the disease, there can also be red blood cell breakdown and low levels of blood platelets, as well as dysfunction of the liver, kidney insufficiency, edema, shortness of breath due to pulmonary edema, or visual disturbance. Pre-eclampsia is diagnosed as a hypertensive disorder of pregnancy; its global prevalence is approximately 1-5% of pregnancies, and this condition is recognized to be one of the leading causes of maternal mortality.

Hypertensive disorders of pregnancy (including pre-eclampsia) are the second most frequent cause of death in maternity-related cases all over the world and are estimated to result in 62,000-77,000 deaths each year. Rising awareness about this disorder and its diagnostic procedure in pregnant women are anticipated factors for the growth of the preeclampsia diagnostic market in the forecast period. For instance, on 19 May 2023, Thermo Fisher Scientific Inc. announced its approval from the U.S. Food and Drug Administration (USFDA) for the first blood test to predict preeclampsia in pregnant women. This blood test is meant for women in their 23rd to 35th weeks of pregnancy.

Increasing Prevalence of Preeclampsia to Drive Market Growth

The increasing incidence of preeclampsia is a major growth factor for the preeclampsia diagnostics market. Factors contributing to the increase include more pregnancies among older women who are at higher risk of developing preeclampsia and lifestyles that have led to obesity and chronic conditions such as diabetes and hypertension. Increased access and availability of prenatal care compounds and socioeconomic factors lead to a high percentage of conditions being undiagnosed or poorly treated. An increase in knowledge about preeclampsia and its life-threatening complications has led to more aggressive action from healthcare providers to screen and monitor the condition early in pregnancy, stressing the need for early intervention to avoid poor outcomes for the mother and child. This increasing prevalence calls for the need to find effective ways of preventing preeclampsia and ensuring healthier pregnancies. For instance, on 31 May 2023, CSEM announced a collaboration with MOMM Diagnostics to develop a cutting-edge point-of-care solution for preeclampsia diagnostics.

Technological Advancements to Drive the Preeclampsia Diagnostics Market Growth

Technological advancements are a key driver for the growth of the preeclampsia diagnostic market as they change how practitioners diagnose and manage this life-threatening condition. Based on innovation, research into biomarkers has led to tests that are sensitive and specific enough to enable the diagnosis of preeclampsia earlier and with greater accuracy than in the past. Moreover, advancements in imaging technologies such as ultrasound and Doppler assessments make it increasingly easier to check fetal well-being and placental health. Integrating artificial intelligence and machine learning makes predictive analytics more personalized about risk, enabling selective interventions. These technological improvements would make the diagnostic process faster and enable healthcare professionals to make more informed decisions, ultimately leading to better maternal and fetal health outcomes. For instance, on 23 September 2024, Unitaid published a report on tools and interventions for the diagnosis and management of pre-eclampsia. The report identifies several new diagnostic tools with promise, holding out the prospect of identifying a woman's risk of contracting pre-eclampsia or even the worsening of the condition. There are two blood biomarker-based SFlt-1 tests, and the placental growth factor can easily be adapted for low-resource settings and further improve treatment options for women diagnosed with a risk of preeclampsia.

Testing Segment to Dominate the Preeclampsia Diagnostics Market Share

The testing segment is expected to dominate the market throughout the forecast period due to its key role in early diagnosis and management of the disease. Increasing numbers of testing modalities, such as blood tests for biomarkers soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF) levels and urine tests to determine protein levels, are routinely offered during the standard prenatal care process. Such tests will help healthcare providers identify the risks patients face and provide early intervention time that would improve their maternal and fetal health. Other than this, personalized medicine has resulted in the formulation of testing protocols that are gradually designed and tailored to the risk profile of individuals. As education about preeclampsia disseminates and healthcare providers increasingly adopt these advanced technologies for testing, the demand for innovative, time-saving diagnostic solutions will continue to increase. For instance, in July 2022, PerkinElmer, Inc., a global leader in innovation, announced that a placental growth factor (PlGF) measurement using its DELFIA Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD), have been included in updated diagnostic guidance issued by the United Kingdom's National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm pre-eclampsia.

North America Dominates the Preeclampsia Diagnostics Market Share

North America dominates the share of the preeclampsia diagnostics market, driven by a combination of advanced healthcare infrastructure with higher levels of awareness, along with significant investment in research. Preeclampsia is a pregnancy-specific disease that affects 2-8% of all pregnancies and is the most significant cause of morbidity and mortality among mothers and neonates in the United States. It has well-established healthcare providers with state-of-the-art diagnostic technologies, thus allowing for relatively prompt and accurate identification of cases of preeclampsia. Another driving force behind the demand for effective diagnostic solutions is the growing attention to antenatal care and early intervention, coupled with governmental efforts to improve maternal health outcomes. The rising prevalence of risk factors such as obesity and advanced maternal age in North America also contributes to the increase in the prevalence of preeclampsia. With a high emphasis on keeping the mother's health as the top priority, it is found that North America still dominates the preeclampsia diagnostics market. For instance, on 31 January 2024, LabCorp, a global leader in innovative and comprehensive laboratory services, announced the US Food and Drug Administration's approval for blood tests for risk assessment and clinical management of severe preeclampsia.

Future Market Scenario (2024-2031F)

The future market scenario of the preeclampsia diagnostics market appears quite promising because of ongoing technological advancements and the growing interest in maternal health. Continued research to identify new biomarkers and methodologies for testing improve diagnostics substantially in terms of accuracy and reliability. Predictive analytics based on artificial intelligence and machine learning approaches can facilitate more personalized and proactive management approaches in risk management for preeclampsia. It will increase awareness of primary caregivers and expectant mothers for earlier interventions. It opens new market opportunities for new therapeutic interventions and better diagnostics to change the matrix of maternal care, facilitating improved results for mother and child. As health systems worldwide move forward and focus on more prenatal care than ever, the preeclampsia diagnostics market will grow in the forecast years due to innovation, collaboration, and a goal towards improved standards in maternal health. For instance, in August 2024, ARUP Laboratories announced its Food and Drug Administration approval for blood-based biomarkers tests to assess risk for preeclampsia. This test quantitates the ratio between two angiogenic factors released by the placenta implicated in the pathophysiology of preeclampsia.

Key Players Landscape and Outlook

The global preeclampsia diagnostics market is highly dynamic, driven by key players engaged in strategic business agreements, collaborations, and regulatory product approvals. Additionally, smaller companies are an integral part of the market landscape, often leveraging partnerships with established players to enhance their reach and address broader market needs. This collaborative environment fosters innovation and supports market growth, meeting the expanding demand for diagnostic solutions.

On 25 September 2024, Trinity Biotech plc, a commercial-stage biotechnology company, announced that it acquired Metabolomics Diagnostics, an Irish deep-tech company specializing in the development of novel biomarker-based diagnostic solutions for predicting the risk of preeclampsia in pregnant women.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Preeclampsia Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. Blood Tests
      • 4.2.1.2. Urine Analysis
      • 4.2.1.3. Others
    • 4.2.2. By Product
      • 4.2.2.1. Instruments
      • 4.2.2.2. Consumables
    • 4.2.3. By End-user
      • 4.2.3.1. Hospitals
      • 4.2.3.2. Diagnostic Centers
      • 4.2.3.3. Specialty Clinics
      • 4.2.3.4. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Test Type
    • 4.3.2. By Product
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. North America Preeclampsia Diagnostics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Test Type
      • 5.2.1.1. Blood Tests
      • 5.2.1.2. Urine Analysis
      • 5.2.1.3. Others
    • 5.2.2. By Product
      • 5.2.2.1. Instruments
      • 5.2.2.2. Consumables
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Specialty Clinics
      • 5.2.3.3. Diagnostic Centers
      • 5.2.3.4. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Preeclampsia Diagnostics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Test Type
          • 5.3.1.2.1.1. Blood Tests
          • 5.3.1.2.1.2. Urine Analysis
          • 5.3.1.2.1.3. Others
        • 5.3.1.2.2. By Product
          • 5.3.1.2.2.1. Instrument
          • 5.3.1.2.2.2. Consumables
        • 5.3.1.2.3. By End-user
          • 5.3.1.2.3.1. Hospitals
          • 5.3.1.2.3.2. Specialty Clinics
          • 5.3.1.2.3.3. Diagnostic Centers
          • 5.3.1.2.3.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Preeclampsia Diagnostics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Preeclampsia Diagnostics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Preeclampsia Diagnostics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Preeclampsia Diagnostics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Thermo Fisher Scientific, Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Diabetomics, Inc.
    • 20.3.3. BioCheck.
    • 20.3.4. Sera Prognostics.
    • 20.3.5. Bayer, AG.
    • 20.3.6. Siemens Healthineers AG.
    • 20.3.7. QuidelOrtho Corporation.
    • 20.3.8. Beckman Coulter, Inc.
    • 20.3.9. PerkinElmer, Inc.
    • 20.3.10. Biora Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer